How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | MRNAModerna, Inc. | ABBVAbbVie Inc. | 950220.KQ950220.KQ | AMGNAMGEN INC | Median of the restexcluding MRNA |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $245.81▲ 3.73 (1.54%) | $285.19▲ 0.39 (0.14%) | ₩1600.00▼ 150.00 (8.57%) | $438.34▼ 0.60 (0.14%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 6.0/10 | 7.0/10 | 2.0/10 | 8.0/10 | 7.0/10 |
| Market value | $96.85B | $503.46B | $10.73B | $236.18B | |
| Revenue | $1.94B | $61.16B | $94.8M | $36.75B | |
| Profit | -$2.82B | $4.23B | -$31.80B | $7.71B | |
| Revenue growthChange in sales versus the prior year. | -39.9% | 8.6% | -44.3% | 10.0% | 8.6% |
| Gross marginShare of sales left after the direct cost of producing them. | 55.3% | 70.2% | 100.0% | 67.2% | 70.2% |
| Operating marginShare of sales left after running the business, before interest and tax. | -158.1% | 24.6% | -26596.5% | 24.7% | 24.6% |
| Profit marginProfit kept from each dollar of sales. | -145.2% | 6.9% | -33531.4% | 21.0% | 6.9% |
| Free cash flow marginCash left after capital spending, as a share of sales. | -106.2% | 29.1% | -34003.6% | 22.0% | 22.0% |
| Return on equityProfit against the owners' stake in the company. | -32.6% | -129.2% | -53.7% | 89.1% | -53.7% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | -36.5% | 16.5% | -71.1% | 14.4% | 14.4% |
| P/E ratioPrice paid per dollar of annual profit. | — | 119.13x | — | 30.63x | 74.88x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | — | 35.69x | — | 19.77x | 27.73x |
| Price to book | 11.20x | -153.96x | 0.18x | 27.28x | 0.18x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.43x | -41.97x | 0.39x | 9.46x | 0.39x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 3/9 | 8/9 | 3/8 | 8/9 | 8.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | grey | distress | grey |
How MRNA compares with the others
- MRNA's operating margin of -158.1% is lower than the median of the other companies selected (24.6%).
- Its revenue grew more slowly than the median of the other companies selected: -39.9% against 8.6%.
- It has no P/E to set against theirs, because it did not make a profit.
- Its liabilities are higher relative to equity than the median of the other companies selected: 0.4x against 0.4x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.